Harrow Secures LogiCare3PL Partner; Analyst Sees 104% Upside to $73.25 Fair Value
Harrow tapped LogiCare3PL as US distribution partner for its ophthalmic solutions, completing onboarding in four weeks to launch non-title and title distribution services effective February 1, 2026. A Strong Buy rating targets a $73.25 fair value, implying 104% upside on pipeline growth and modeled 32–45% EBIT margins by 2035.
1. Distribution Partnership with LogiCare3PL
In February 2026 Harrow appointed LogiCare3PL to handle non-title and title distribution of its ophthalmic disease management products across the US. The provider delivered high-touch onboarding within four weeks and initiated full logistics services effective February 1, 2026.
2. Operational Benefits
The partnership offers Harrow rapid market access and potential reductions in distribution costs through LogiCare3PL’s integrated warehousing, compliance support and time- and temperature-sensitive logistics. Swift onboarding preserved business continuity and positions Harrow to scale deployment of dry eye and AMD therapies.
3. Analyst Valuation and Growth Forecast
An analyst assigned a Strong Buy rating with a $73.25 fair value, suggesting 104% upside from current levels. The valuation reflects expected pipeline contributions—Vevye, Iheezo—alongside modeled 32–45% EBIT margins between 2029 and 2035 backed by an 11.3% WACC.